BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 199 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.63 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $504,000 | +17.5% | 31,000 | 0.0% | 0.03% | +14.8% |
| Q4 2021 | $429,000 | -3.6% | 31,000 | 0.0% | 0.03% | -20.6% |
| Q3 2021 | $445,000 | -9.2% | 31,000 | 0.0% | 0.03% | -10.5% |
| Q2 2021 | $490,000 | +60.7% | 31,000 | +3.3% | 0.04% | +46.2% |
| Q1 2021 | $305,000 | – | 30,000 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $62,538,000 | 25.44% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,720,733 | $27,979,000 | 5.53% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 57,000 | $19,282,000 | 4.35% |
| MPM BioImpact LLC | 639,089 | $10,392,000 | 2.79% |
| Parkman Healthcare Partners LLC | 476,978 | $7,756,000 | 2.27% |
| Sarissa Capital Management LP | 1,390,790 | $22,614,000 | 2.14% |
| Ghost Tree Capital, LLC | 350,000 | $5,691,000 | 1.24% |
| Lisanti Capital Growth, LLC | 662,644 | $10,775,000 | 1.21% |
| Baker Brothers Advisors | 12,710,818 | $206,678,000 | 1.19% |
| Tamarack Advisers, LP | 125,000 | $2,033,000 | 0.96% |